Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Timothy Busfield turns himself in to face child sexual abuse charges in New Mexico - 22024 Manual for Light Extravagance Room Feel: What's Moving
- 3Poland open to German troops to help secure Ukraine ceasefire
- 4Authorities arrest 7 bodyguards in connection with a Mexican mayor's assassination
- 5‘RuPaul's Drag Race’ Season 18: How to watch without cable, premiere time, cast list and more
- Don't plan to cook on Thanksgiving? Here are the restaurants and fast food places that are scheduled to be open
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- Impact of NIH funding reductions felt in cancer and infectious disease trials
- The Best Internet based Retailers for Style and Frill
- Closets for Your Room: Plan and Utility Features
- Agios Pharma shares jump as US FDA expands approval for its blood disorder drug
- Over 60 local leaders push Netanyahu to halt haredi draft bill, warn of social rift
- Mickey Lee of 'Big Brother' fame dead at 35 after flu complications, family says
- If someone's always late, is it time blindness, or are they just being rude?
